NeuBase Therapeutics
In David Einhorn's portfolio · Greenlight Capital
Ticker NBSE
Not in the portfolio as of Q3 2026. Every quarter it shows up in a Greenlight Capital 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q2 2024 | Sell | 0 | |
| Q1 2024 | No change | 136,350 | 0.0% |
| Q4 2023 | No change | 136,350 | 0.0% |
| Q3 2023 | No change | 136,350 | 0.0% |
| Q2 2023 | Reduce 95% | 136,350 | 0.0% |
| Q1 2023 | No change | 2,727,027 | 0.0% |
| Q4 2022 | No change | 2,727,027 | 0.0% |
| Q3 2022 | No change | 2,727,027 | 0.1% |
| Q2 2022 | No change | 2,727,027 | 0.2% |
| Q1 2022 | No change | 2,727,027 | 0.3% |
| Q4 2021 | No change | 2,727,027 | 0.4% |
| Q3 2021 | No change | 2,727,027 | 0.7% |
| Q2 2021 | Add 35% | 2,727,027 | 0.8% |
| Q1 2021 | No change | 2,027,027 | 1.0% |
| Q4 2020 | No change | 2,027,027 | 0.9% |
| Q3 2020 | Add 7% | 2,027,027 | 1.3% |
| Q2 2020 | Add 24% | 1,903,227 | 1.8% |
| Q1 2020 | No change | 1,538,462 | 1.6% |
| Q4 2019 | No change | 1,538,462 | 0.8% |
| Q3 2019 | Buy | 1,538,462 | 0.6% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.